CAS 1440964-89-5

Bozitinib

CAS : 1440964-89-5

Bozitinib (PLB-1001) (PLB-1001) is a highly selective inhibitor of the c-MET kinase with blood-brain barrier permeability.

Formule : C₂₀H₁₅F₃N₈

Degré de pureté : 99.16%

Couleur et forme : Solid

Masse moléculaire : 424.38

Ref: TM-T10585

Bozitinib (PLB-1001)

CAS : 1440964-89-5

Formule : C₂₀H₁₅F₃N₈

Degré de pureté : 98%

Masse moléculaire : 424.3819

Ref: IN-DA01WTC0

Bozitinib

CAS : 1440964-89-5

Bozitinib

Degré de pureté : ≥98%

Masse moléculaire : 424.38g/mol

Ref: 54-BUP02411

Bozitinib (PLB-1001)

CAS : 1440964-89-5

Formule : C₂₀H₁₅F₃N₈

Masse moléculaire : 424.39

Ref: 4Z-B-268001

Bozitinib (PLB-1001)

CAS : 1440964-89-5

Bosutinib is a CDK4/6 inhibitor that inhibits the activity of proteins that regulate cell division. Bosutinib has been shown to have anti-cancer properties by inhibiting the growth of cancer cells in preclinical models. Bosutinib also inhibits epidermal growth factor (EGF) and tumor necrosis factor (TNF). Bosutinib has been shown to have clinical benefit in patients with subcutaneous tumors, glioma, and other cancers. Bosutinib has not been evaluated in pregnant women or children and should be used only if potential benefits outweigh risks.

Formule : C₂₀H₁₅F₃N₈

Degré de pureté : Min. 95%

Masse moléculaire : 424.38 g/mol

Ref: 3D-QHC96489